Shares of ProKidney Corp. PROK skyrocketed 515% yesterday after the company reported encouraging top-line data from the phase ...

Researchers at the Chinese Academy of Sciences and collaborators have developed a new method to label and monitor dormant breast cancer cells over time, shedding light on how these cells survive ...

ProKidney Corp. (PROK) shares just saw a massive green day. Results from Phase 2 were compelling and the data sharply ...

US clinical-stage biotech ProKidney reported statistically-significant and clinically-meaningful positive top-line results ...

The company also encounters competitive risks from other organizations developing therapies for chronic kidney disease.

ProKidney shares surged 500% on positive Phase 2 CKD results. Read why I remain cautious about PROK stock despite the recent ...

Over the last 7 days, the United States market has remained flat, though it is up 13% over the past year with an optimistic forecast for earnings growth. In such a landscape, identifying stocks with ...

ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company”), a leading late clinical-stage cellular therapeutics company ...

Shares of ProKidney surged more than 500% on Tuesday following upbeat results from its Phase 2 REGEN-007 study and a price ...

U.S. stocks settled mostly lower on Tuesday, with the Dow Jones index falling more than 150 points during the session ...

ProKidney (NASDAQ: PROK) experienced a surge of 515% during Tuesday's trading session and gained additional 8.58% after-hours ...

A mixed bag of top-line phase II data prompted stellar stock results for Prokidney Corp. and its chronic kidney disease (CKD) ...